Sustained virologic response was 20.8 % ( 95 % CI 13-29 ) with IFN monotherapy and 54.2 % ( 95 % CI 44-64 ) with combination ( P = 0.0001 ) , the relapse rate 39.4 % ( 95 % CI 23-56 ) and 9 % ( 95 % CI 1-16 ) ( P = 0.0007 ) , and the combined rate of sustained biochemical and virologic response 22.7 % ( 95 % CI 14-31 ) and 60.5 % ( 95 % CI 50-71 ) ( P = 0.0001 ) , respectively .
